MX2018004580A - Metodo para producir proteina de fusion con dominio fc de igg. - Google Patents

Metodo para producir proteina de fusion con dominio fc de igg.

Info

Publication number
MX2018004580A
MX2018004580A MX2018004580A MX2018004580A MX2018004580A MX 2018004580 A MX2018004580 A MX 2018004580A MX 2018004580 A MX2018004580 A MX 2018004580A MX 2018004580 A MX2018004580 A MX 2018004580A MX 2018004580 A MX2018004580 A MX 2018004580A
Authority
MX
Mexico
Prior art keywords
fusion protein
igg
domain
producing fusion
preparing
Prior art date
Application number
MX2018004580A
Other languages
English (en)
Inventor
Jae Park Soon
Shin Chung Hye
Ah You Sun
Soo Cho Jeong
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58703642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018004580(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alteogen Inc filed Critical Alteogen Inc
Priority claimed from PCT/KR2016/011561 external-priority patent/WO2017065559A1/ko
Publication of MX2018004580A publication Critical patent/MX2018004580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)

Abstract

La presente invención se refiere a un método para preparar una proteína de fusión con un dominio Fc de lgG y, específicamente, a un método para preparar una proteína de fusión con un dominio Fc de lgG, comprendiendo adicionalmente el método una etapa de cultivo de células, que producen la proteína de fusión., a una temperatura de cultivo disminuida, aumentando así el crecimiento celular y la viabilidad celular a fin de aumentar la productividad de la proteína de fusión e inhibir la generación de agregados para de esta forma mejorar la calidad y el rendimiento de la producción.
MX2018004580A 2015-10-15 2016-10-14 Metodo para producir proteina de fusion con dominio fc de igg. MX2018004580A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150144330 2015-10-15
KR1020160132633A KR101936049B1 (ko) 2015-10-15 2016-10-13 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
PCT/KR2016/011561 WO2017065559A1 (ko) 2015-10-15 2016-10-14 Igg fc 도메인을 가지는 융합 단백질의 생산방법

Publications (1)

Publication Number Publication Date
MX2018004580A true MX2018004580A (es) 2018-09-19

Family

ID=58703642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004580A MX2018004580A (es) 2015-10-15 2016-10-14 Metodo para producir proteina de fusion con dominio fc de igg.

Country Status (12)

Country Link
US (2) US11414476B2 (es)
EP (2) EP3363811B1 (es)
JP (2) JP6783305B2 (es)
KR (1) KR101936049B1 (es)
CN (2) CN108137672B (es)
AU (1) AU2016339642B2 (es)
BR (1) BR112018007590A2 (es)
CA (1) CA3001977C (es)
ES (1) ES2945537T3 (es)
MX (1) MX2018004580A (es)
PL (1) PL3363811T3 (es)
RU (1) RU2732237C2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
EP3612637A4 (en) 2017-04-21 2021-01-27 Yuhan Corporation DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES
CN115197961B (zh) * 2022-06-20 2024-04-16 岭南现代农业科学与技术广东省实验室肇庆分中心 一种非洲猪瘟病毒b602l重组蛋白稳定表达细胞系及其构建方法和应用
WO2024143785A1 (ko) * 2022-12-27 2024-07-04 주식회사 넥스세라 엘라스틴 유사 폴리펩타이드 기반 재조합 단백질 제작 및 이의 동물세포 발현 플랫폼

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
BRPI0011407B8 (pt) 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
WO2003020906A2 (en) * 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2188371B1 (en) 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
EP3165606A1 (en) 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
MX2012012528A (es) * 2010-04-26 2012-11-23 Novartis Ag Proceso de cultivo celular mejorado.
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
SG11201500480TA (en) 2012-08-02 2015-02-27 Sanofi Sa Article of manufacture comprising aflibercept or ziv-aflibercept
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CA2907771C (en) 2013-03-26 2023-01-10 Coherus Biosciences, Inc. Perfusion method for manufacturing etanercept
BR112015025960A2 (pt) 2013-04-15 2017-07-25 Ericsson Telefon Ab L M método, nó de rede e equipamento de usuário para atualizar informação de sistema
CN103319610B (zh) 2013-07-05 2016-01-27 华博生物医药技术（上海）有限公司 重组融合蛋白及其制法和用途
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
KR102519540B1 (ko) 2014-01-29 2023-04-10 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
CN104974262B (zh) * 2014-04-04 2019-08-09 华博生物医药技术（上海）有限公司 重组双功能融合蛋白及其制法和用途
CN106536746A (zh) * 2014-06-03 2017-03-22 鲁宾有限公司 用于生产蛋白的细胞培养方法
KR20160132633A (ko) 2015-05-11 2016-11-21 주식회사 엘지화학 배터리 시스템 및 그 연결 제어 방법
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基

Also Published As

Publication number Publication date
EP4098659A1 (en) 2022-12-07
PL3363811T3 (pl) 2023-07-17
RU2018117705A (ru) 2019-11-15
RU2018117705A3 (es) 2019-11-15
EP3363811A4 (en) 2019-03-13
EP3363811A1 (en) 2018-08-22
CN115247196A (zh) 2022-10-28
US11414476B2 (en) 2022-08-16
KR20170044594A (ko) 2017-04-25
KR101936049B1 (ko) 2019-01-08
US20220348636A1 (en) 2022-11-03
CN108137672B (zh) 2022-09-06
US20180298078A1 (en) 2018-10-18
CA3001977C (en) 2023-06-20
EP3363811B1 (en) 2023-04-19
AU2016339642A1 (en) 2018-04-12
RU2732237C2 (ru) 2020-09-14
JP6783305B2 (ja) 2020-11-11
AU2016339642B2 (en) 2019-07-25
ES2945537T3 (es) 2023-07-04
BR112018007590A2 (pt) 2018-10-23
JP2020114266A (ja) 2020-07-30
CN108137672A (zh) 2018-06-08
CA3001977A1 (en) 2017-04-20
JP2018530344A (ja) 2018-10-18

Similar Documents

Publication Publication Date Title
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
CY1118863T1 (el) Καλλιεργεια κυτταρου θηλαστικου
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
WO2011134919A3 (en) Cho cells cultivation process 0
MX2016012419A (es) Formas solidas de ibrutinib y procesos para la produccion de las mismas.
MX2015016947A (es) Metodos para producir derivados de acido graso omega-hidroxilados.
WO2017051347A3 (en) Cells and method of cell culture
MX2023009109A (es) Una variante de isopropilmalato sintasa novedosa y un procedimiento de produccion de l-leucina usando la misma.
MX2018002705A (es) Cepas de levadura para la expresion y secrecion de proteinas heterologas a altas temperaturas.
BR112017021255A2 (pt) microrganismo modificado para a produção otimizada de 2,4-di-hidroxibutirato
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
MX2019008417A (es) Cambio de temperatura para una expresion con mayor rendimiento de polipeptidos en levaduras y otras celulas transformadas.
WO2016171224A9 (ja) タンパク質の分泌生産法
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
WO2015004403A3 (fr) Procede de culture cellulaire decouple
MX2016010236A (es) Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
WO2018203947A3 (en) MODIFIED BIOSYNTHESIS PATHWAYS FOR FERMENTATION TYRAMINE PRODUCTION
PH12016502406A1 (en) Cell culture process for producing a protein
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
EP3511410A4 (en) MEDIUM FOR THE CULTURE OF STEM CELLS, METHOD FOR THE CULTURE OF STEM CELLS, STEM CELL GROWTH PROMOTER AND COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
EP3778880A4 (en) Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells
EP3415632A4 (en) PROCESS FOR PRODUCING SACCHARIFIED LIQUID USING AN ENZYMATIC PROCESS USING CELLULOSE BIOMASS AS A RAW MATERIAL
MY180645A (en) Microbial production of fatty amines
NZ749715A (en) Leuconostoc mesenteroides cjlm119 strain producing reduced amount of gas, and kimchi production method using same
MX2017012223A (es) Metodo de produccion con iones de cobre controlados.